Trial reportNature medicine2019
Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model.
Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model.PLoS neglected tropical diseases · 2020Trial
- The Manipulation of Host Cells byInternational journal of molecular sciences · 2026Review
- A new mouse model of typhoid fever usingmBio · 2026Article
- Typhoid toxin of Salmonella Typhi elicits host antimicrobial response during acute typhoid fever.EMBO molecular medicine · 2026Article
- Longitudinal kinetics of the viral infection biomarker 3'-deoxy-3',4'-didehydro-cytidine in SARS-CoV-2, influenza A virus and RSV human challenge models.Npj viruses · 2025Article
- Article
- Mitochondrial injury induced by a Salmonella genotoxin triggers the proinflammatory senescence-associated secretory phenotype.Nature communications · 2024Article
- The Identification of Enteric Fever-Specific Antigens for Population-Based Serosurveillance.The Journal of infectious diseases · 2024Article
- Protocol for the challenge non-typhoidalBMJ open · 2024Article
- Typhoid fever.Nature reviews. Disease primers · 2023Review
- The diverse landscape of AB5-type toxins.Engineering microbiology · 2023Review
- Early transcriptional responses to human enteric fever challenge.Infection and immunity · 2023Article
- Variations of blood viscosity in acute typhoid fever: A cross-sectional study.Journal of medicine and life · 2023Article
- Article
- One species, different diseases: the unique molecular mechanisms that underlie the pathogenesis of typhoidal Salmonella infections.Current opinion in microbiology · 2023Review
- Identification of collaborative cross mouse strains permissive to Salmonella enterica serovar Typhi infection.Scientific reports · 2023Article
- Article
- The evolutionary diversification of theFrontiers in microbiology · 2022Article
- Article
- Host restriction, pathogenesis and chronic carriage of typhoidal Salmonella.FEMS microbiology reviews · 2021Review
Corrections and comments
- Commented on by
Authors and funding
27 authors at 5 institutions in 2 countries.
Malick M GibaniOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. malick.gibani@paediatrics.ox.ac.uk.ORCID http://orcid.org/0000-0003-1781-0053
Elizabeth JonesOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Amber BartonOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Celina JinOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Juliette MeekOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Susana CamaraOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Ushma GalalNuffield Department of Primary Care Health Sciences, Clinical Trials Unit, University of Oxford, Oxford, UK.
Eva HeinzWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0003-4413-3756
Yael Rosenberg-HassonHuman Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.
Gerlinde ObermoserHuman Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.
Claire JonesOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Danielle CampbellOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.ORCID http://orcid.org/0000-0001-5794-8036
Charlotte BlackOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Helena Thomaides-BrearsOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Christopher DarlowOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Christina DoldOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Laura Silva-ReyesOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Luke BlackwellOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Maria Lara-TejeroDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA.
Xuyao JiaoDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA.
Gabrielle StackDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA.
Christoph J BlohmkeOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Jennifer HillOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Brian AngusNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3598-7784
Gordon DouganWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Jorge GalánDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-6531-0355
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
University of Oxford · GBYale University · USStanford University · USEuropean Bioinformatics Institute · GBLiverpool School of Tropical Medicine · GB
Funding
Medical Research Council MR/N025989/1Wellcome Trust
Abstract
Salmonella Typhi is a human host-restricted pathogen that is responsible for typhoid fever in approximately 10.9 million people annually
Indexed as
Acute DiseaseAdolescentAdultAnimalsBacterial ToxinsDouble-Blind MethodHumansMiceMice, Inbred C57BLMiddle AgedSalmonella typhiTyphoid FeverYoung AdultBacterial Toxins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.